LOS ANGELES, March 26, 2018 /PRNewswire/
-- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular")
(NYSE American: IMUC) today announced that, as previously disclosed
in its Annual Report on Form 10-K for the year ended December
31, 2017 filed with the Securities and Exchange
Commission on March 14, 2018, the audited financial
statements contained an audit opinion from its independent
registered public accounting firm that included a going concern
emphasis of matter paragraph (see further discussion in footnote 2
to the Company's financial statements included in the Company's
Annual Report on Form 10-K). This announcement is made pursuant to
NYSE American Company Guide Section 610(b), which requires public
announcement of the receipt of an audit opinion containing a going
concern paragraph. This announcement does not represent any change
or amendment to the Company's financial statements or to its Annual
Report on Form 10-K for the year ended December 31, 2017.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd., based in Los Angeles, is developing immune-based
therapies for the treatment of cancer. ImmunoCellular is focused on
advancing its Stem-to-T-Cell research program, which engineers
hematopoietic stem cells to generate cytotoxic T cells. Additional
assets, for which the Company is seeking partners, include
clinical-stage programs - ICT-107, ICT-121 and ICT-140 - which are
patient-specific, dendritic cell-based immunotherapies targeting
solid tumors. To learn more about ImmunoCellular, please visit
www.imuc.com.
Contact:
ImmunoCellular Thereapeutics, Ltd.
Jane Green
(267) 457-3734 direct
(415) 652-4819 mobile
jane@jmgcomm.com
Lytham Partners, LLC
Joe Dorame, Robert Blum, or
Joseph Diaz
(602) 889-9700
imuc@lythampartners.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/immunocellular-therapeutics-receives-audit-opinion-with-going-concern-explanation-300619112.html
SOURCE ImmunoCellular Therapeutics, Ltd.
